AK119 + AK112 + FOLFIRI

AK119 + AK112 + FOLFIRI is an investigational combination therapy for cancer treatment that includes two novel antibodies (AK119 and AK112) alongside FOLFIRI, a standard chemotherapy regimen. - **FOLFIRI** is a well-established chemotherapy regimen comprising folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. FOLFIRI targets rapidly dividing cancer cells through multiple mechanisms: fluorouracil is an antimetabolite that disrupts DNA synthesis and RNA function, folinic acid enhances fluorouracil efficacy by increasing its binding to thymidylate synthase, and irinotecan inhibits topoisomerase I, causing DNA strand breaks during replication and cell death[1][2][3]. - **AK119** and **AK112** are monoclonal antibodies; although their exact mechanisms are not detailed in results found, such agents are typically developed to target specific immune checkpoints or signaling pathways involved in tumor growth and immune evasion. These antibodies are in clinical development and may act as immunotherapy agents that enhance anti-tumor activity, possibly by modulating immune cell activity or blocking inhibitory pathways. This combination is under investigation for use primarily in advanced or metastatic colorectal cancer and possibly other gastrointestinal cancers, aligning with the indications and administration of FOLFIRI[1][2][3]. The regimen would be administered intravenously.